Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Escherichia coli strain:EC555

ABSTRACT: Comparison of Whole Genome sequence (WGS)of a Clinical E.coli Strain(EC555)-with the WGS of same strain treated with a very potent antibacterial agent PPEF

PROVIDER: PRJNA616230 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11475092_1.fastq.gz	Fastqsanger.gz
	SRR11475092_2.fastq.gz	Fastqsanger.gz
	SRR11475093_1.fastq.gz	Fastqsanger.gz
	SRR11475093_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Escherichia coli

Project description:Comparison of Whole transcriptome sequence of Clinical E.coli Strain (EC555)-with WTS of an antibiotic agent namely PPEF treated EC555

| PRJNA616186 | ENA

Escherichia coli

Project description:Comparison of Whole Genome sequence of E. coli K-12 wild type strain with WGS of E. coli K-12-R, highly tolerant to PPEF an antibacterial agent.

| PRJNA616205 | ENA

Escherichia coli

Project description:Comparison of transcriptome of E. coli K-12 wild type strain with transcriptome of E. coli K-12-R, highly tolerant to PPEF an antibacterial agent.

| PRJNA623259 | ENA

Comparison of IS5 Deletion mutant to E.coli Motile and NonMotile Isolates

Project description:These series of experiments compares the expression profile of the motility variants of E.coli MG1655 ( Motile and NonMotile isolates) to an isogenic E.coli MG1655 strain in which the IS5 upstream of flhDC has been deleted. The expression profiles of genes in the E.coli MG1655 motile isolate and E.coli MG1655 Non_Motile isolate also compared. Keywords: parallel sample

2005-06-02 | GSE2694 | GEO

Strain dependent rate of evolution in the gut of lean and obese mice

Project description:WGS: E.coli populations sequencing

| PRJEB48324 | ENA

Project description:WGS of E.coli isolate

| PRJNA432293 | ENA

Proteomic study of evolved P. aeruginosa strains grown in S. aureus- and K. pneumoniae-conditioned media

Project description:In this research, Pseudomonas aeruginosa underwent evolution in the supernatant of either S. aureus (SA) or K. pneumoniae (KP). Through this evolution process, we enriched a sufficient number of bacterial cells along with their corresponding proteins. Following 15 cultivation cycles, notable changes were observed in the phenotypes of P. aeruginosa, with a series of mutations identified through whole-genome sequencing (WGS). Proteomics analysis unveiled that the supernatant-evolved mutants displayed distinct regulation patterns in crucial pathways (including the type VI secretion system, biofilm formation, phenazine biosynthesis, translation, beta-lactam resistance, and O-antigen biosynthesis) in comparison to both the ancestral strain and the unmodified medium-evolved (UmMd-evolved) strain.

2025-05-21 | PXD059669 | Pride

Confirmation of glucose transporters through targeted mutagenesis and transcriptional analysis in Clostridium acetobutylicum

Project description:Glucose uptake in Escherichia coli had been studied extensively, but the lack of basic information of glucose uptake systems in C. acetobutylicum has limited the understanding of glucose assimilation in this strain. There is a main glucose transporter which is very efficient for glucose uptake and the maltose, mannose and galactose transport systems are also able to transport glucose into cytoplasm of E.coli. Therefore, it is very interesting to investigate whether a similar glucose transport mechanism exists in C. acetobutylicum.

2022-12-28 | E-MTAB-12054 | biostudies-arrayexpress

Crizotinib, Tyrosine Kinase Inhibitors, Create an Antibacterial Active against Gram-positive Bacteria by Targeting the CTP Synthetase PyrG

Project description:Abstract The infection of drug resistant bacteria seriously threats to public health, which makes it more urgent to find novel antibacterial compounds. Compared with traditional development approaches, drug repurposing provides a faster and more effective strategy to find new antimicrobial agents. Here, we screened an FDA-approved small-molecule library upon S. aureus, and identified crizotinib as an antimicrobial agent. We confirmed the antibacterial activities of crizotinib in vitro and in vivo by MIC, growth curve, SEM and mice experiment. At the same time, crizotinib also showed low tendency to develop resistance. Mechanistically, quantitative proteomics, bioinformatics analyses, qRT-PCR and flow cytometry biochemical validation experience confirmed that crizotinib exerted its antibacterial effects by interfering pyrimidine metabolism and disrupting DNA synthesis eventually. Furthermore, our data from drug affinity responsive target stability, bio-layer interferometry and a series of functional assays demonstrated that crizotinib could target PyrG directly in pyrimidine metabolism pathway. Taken together, our results indicated that crizotinib could be a potential antimicrobial agent to treat Gram-positive bacterial infections in the future.

2022-03-10 | PXD029546 | Pride

Project description:Dietary palygorskite-based antibacterial agent Supplementation on microbiota

| PRJNA955016 | ENA